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Introduction
Fragment-based design (FBD) has emerged as a powerful tool for the discovery and optimisation of drug-like compounds.
1
Whereas the most common approach for the identication of fragments as hits still remains the screening of fragment libraries, 2 de novo design of fragments is attracting more and more attention, 3 in particular for targets for which an initial screen of a fragment library is impossible owing to the type of assay used or insufficient quantities of protein available. The use of FBD is particularly attractive due to its potential to cover a greater fraction of chemical space and to afford fragments with high ligand efficiencies (LEs, dened as LE ¼ ÀDG/N where DG corresponds to the Gibbs free energy of binding (kcal mol À1 ) and N is the number of non-hydrogen atoms) that should be maintained during the optimisation stages. 4 Despite these advantages, several hurdles persist: the fragment hit identied may not be amenable to follow-up synthesis, which is oen a time-consuming and resource-intensive undertaking. Furthermore, the fragment-to-lead process consists in optimising (e.g., fragment growing, fragment linking) the initial fragment hit towards a more potent lead-like compound.
5 During this process, the binding mode of the initial fragment must be maintained, requiring ideally a co-crystal structure of the (modied) fragment to be solved at every optimisation step. 6 Unfortunately, for approximately 40% of pharmaceutically relevant protein targets, crystal structures of sufficient quality cannot be obtained and for those proteins, which are crystallisable, this is oen a time-and resource-consuming process, as reliable soakable crystallographic systems are not always available. 7 Moreover, it can be very difficult to co-crystallise fragments obtained in the early stage of the fragment-to-lead process because of their weak affinity for the target, requiring prohibitively high ligand concentrations.
NMR spectroscopy can be particularly helpful in these cases, 8 as it is suited for a wide range of binding affinities and can outperform other methods such as screening assays, surface plasmon resonance and uorescence anisotropy in terms of the detection of weak binders. 9 A major advantage of NMR spectroscopy with respect to co-crystal structures is that information about the binding mode in solution is obtained. In addition, the rigid nature of co-crystal structures can lead to misinterpretations of the interactions between the designed ligand and the protein.
10
Whereas protein-observed NMR experiments are limited to small protein targets (M w < 50 kDa), which can be labelled and puried in large amounts, 5b ligand-observed NMR experiments require less, unlabelled protein and enable direct identication of the ligands as long as their chemical shis in solution are known.
11
We recently developed and validated retrospectively an innovative, fast and reliable ligand-based NMR methodology 12 extending the INPHARMA methodology 13 to decipher the binding mode of a ligand in solution using a very low concentration of unlabelled protein (e.g., 30 mM). The latter aspect makes this technique available for all targets with a certain size (M w > 30 kDa), including less established ones for which protein expression is oen the bottleneck. The method covers a wide range of binding affinities (K d from 1.0 mM to 2.0 mM), typically observed for weakly to moderately binding fragments.
A combination of three NMR techniques is applied to elucidate the binding mode of a ligand or fragment: (i) Saturation-Transfer Difference (STD) yields information on the protein-buried and water-exposed parts of the ligand, 14 (ii) Transfer-NOE (trNOE) reveals the bound ligand conformation and (iii) INPHARMA derives the relative binding mode of two ligands interacting with the same binding site.
13 The methodology is termed STI, referring to its three NMR parameters STD, trNOE and INPHARMA and holds the potential to represent an attractive alternative to protein crystallography in both FBD and structure-based design (SBD) projects. An INPHARMA-based identication of the binding site of fragment-like molecules for glycogen phosphorylase has been reported recently, which illustrates the potential of this method.
15
In the present work, we apply the STI methodology for the rst time to the de novo FBD of inhibitors of the enzyme 1-deoxy-Dxylulose-5-phosphate synthase (DXS), illustrating its potential when applied in the early stages of medicinal-chemistry projects.
DXS catalyses the rst and rate-limiting step of the 2C-methyl-D-erythritol-4-phosphate (MEP) pathway (also known as nonmevalonate pathway) for the biosynthesis of isopentenyl diphosphate (IPP, 1) and dimethylallyl diphosphate (DMAPP, 2). 16 IPP and DMAPP are the universal precursors of isoprenoids, a large and important class of natural products (e.g., camphor (3) lanosterol (4) and vitamin A (5), Scheme 1a) featuring very diverse structures and essential biological functions.
17 The rst step of the MEP pathway catalysed by DXS consists in the thiaminediphosphate (TDP)-dependent decarboxylative condensation of pyruvate (6) and D-glyceraldehyde 3-phosphate (7, GAP) to afford 1-deoxy-D-xylulose-5-phosphate (8, Scheme 1a). Whereas pathogens such as Mycobacterium tuberculosis and Plasmodium falciparum, causative agents of tuberculosis and malaria, respectively, use the MEP pathway for the biosynthesis of 1 and 2, humans exclusively utilise the alternative mevalonate pathway, making the enzymes of the MEP pathway attractive drug targets for the development of new drugs against tuberculosis and malaria.
18
Due to the emergence of several multi-and extensively-drugresistant strains of M. tuberculosis and P. falciparum, there is a growing need for the development of new anti-infective agents with new mechanisms of action.
19
The involvement of DXS both in microbial thiamine (vitamin-B 1 ) biosynthesis 20 as well as in vitamin-B 6 biosynthesis 21 renders it a particularly interesting target, with the benet of interfering with three crucial bacterial biosynthetic pathways at once. On the one hand, the similarity between DXS and mammalian TDPdependent enzymes such as transketolase (TK) 22 and pyruvate dehydrogenase (PDH) 23 could give rise to selectivity problems in the development of inhibitors against DXS, especially when targeting the TDP-binding pocket (Fig. S1 , † 20% identity overall, 47% identity in the TDP-binding pocket between human TK and M. tuberculosis DXS). On the other hand, DXS has distinctive features compared to other TDP-dependent enzymes suggesting that selective inhibition of DXS over other TDP-dependent enzymes could be possible: the peculiar domain arrangement of Deinococcus radiodurans DXS (RCSB Protein Data Bank (PDB) code: 2O1X) where the TDP-binding site is located within the same monomer 24 and not at the dimer interface like in its mammalian homologues, 26 the particularly large active site 27 and its unique catalytic mechanism, which requires the formation of a ternary complex with pyruvate and GAP 28 (in contrast, all the other TDP-dependent enzymes follow classical ping-pong kinetics in which the binding of acceptor substrate is preceded by the activation of pyruvate and release of CO 2 ). 29 Therefore, ideally, a DXS-inhibitor should be designed so as to target both the TDPbinding pocket to enhance the affinity and the substrate-binding pocket to afford selectivity.
The two crystal structures of DXS in complex with TDP deposited in the PDB 24 are not of the pathogenic organisms, making the development of inhibitors for this enzyme a challenge. As a result, very few inhibitors of DXS have been reported in the literature (9-14, Scheme 1b)
30 and for none of them the binding mode has been validated. Only phosphonates 12 and 13 have been shown to compete with the binding of pyruvate by kinetic studies.
30d,f

Results and discussion
De novo design and biochemical evaluation of rst-generation fragments As a starting point for our FBD, we decided to target the TDPbinding pocket rather than the ill-dened substrate-binding pocket. Despite the low lipophilic character of the TDP pocket with respect to the average for druggable pockets, 32 it obtained a rather high Dscore when analysed with the programme DogSiteScore. 33 The fragments were designed so that they could be further grown either towards the diphosphate pocket or ideally towards the substrate-binding pocket, where selectivity could be gained.
We used D. radiodurans DXS as a model enzyme for our studies given the high degree of sequence identity between D. radiodurans DXS and M. tuberculosis DXS (38% overall, 68% in the TDP-binding pocket (Fig. S1 †) . 24 As a rst step towards the development of inhibitors for DXS, we focused on designing TDP-competitive fragments and therefore rst analysed the binding mode of TDP, which is deeply buried inside D. radiodurans DXS. As highlighted in Fig. 1a , the aminopyrimidine moiety of TDP is involved in three hydrogen bonds with the
) and a p-stacking interaction with the side chain of Phe398. The catalytically active part of TDP, the thiazolium ring, is surface-exposed and only involved in a few hydrophobic interactions (with Ile187, Ile371 and Val80), while the diphosphate moiety engages in numerous polar interactions both with polar amino-acid side chains and with the protein backbone. The catalytic Mg 2+ ion is complexed by both phosphate groups. The binding of TDP with DXS is rather tight (D. radiodurans Fig. S2 †) . Moreover, by comparing the inhibitory potency of deazathiamine 17 (IC 50 ¼ 430 AE 68 mM) and its diphosphorylated form, deazathiamine diphosphate 18 (IC 50 ¼ 0.034 AE 0.006 mM), 34 it is evident that the diphosphate moiety accounts for a good part of its binding energy. Being aware of the challenges in targeting very polar diphosphate-binding pockets, we decided to occupy the more druggable aminopyrimidine and thiazolium pockets.
Using the modelling soware MOLOC, 35 we designed fragment 15 de novo (Fig 1b, Table 1 ). Docking with the FlexX docking module in the LeadIT suite further guided our 25 modelling studies. 36 The favourable p-stacking interaction with Phe398 is maintained in the same way as for TDP, but the pyridine ring of 15 is slightly displaced with respect to the amino-pyrimidine ring of TDP leading to a more favourable parallel-displaced p-stacking interaction. In the modelled pose, the imidazole ring of 15 is accommodated in the thiazolium pocket and is displaced with respect to the thiazolium ring of TDP. As a result, the van-der-Waals interactions with Ile187 and Ile371 -which help to keep the thiazolium ring in place in the case of TDP -should be strengthened.
According to the modelling studies, the imidazolic N3 is involved in a favourable hydrogen bond with the side chain of Ser186 (d(N/HO-Ser186) ¼ 3.0Å). The 3-methoxy group of the pyridine ring forms a hydrogen bond with the backbone N-H of Ala125 (d(O/HN-Ala125 ¼ 2.8Å), mimicking the hydrogen bond of the N3 of the aminopyrimidine ring of TDP. Not surprisingly, the N1 of the pyridine ring of 15 is not involved in a hydrogen bond with Glu373 anymore, due to the displacement of the ring with respect to the aminopyrimidine ring of TDP. We carried out the synthesis of 15 in four steps using an S N 2 reaction as a key step to link the two aromatic rings (Scheme S1 †). Biochemical evaluation of 15 using a coupled DXS-IspC (1-deoxy-D-xylulose-5-phosphate reductoisomerase) photometric assay showed an IC 50 ¼ 1.8 AE 0.5 mM against D. radiodurans DXS (experimentally derived LE ¼ 0.33 kcal mol À1 ). The imidazolyl ring is a suitable platform to address both the diphosphatebinding pocket and the newly identied pocket lined by residues His304, His82, His51, Phe109 and His43. This pocket, from now on referred to as "histidine-rich pocket", is presumably involved in substrate-binding. Fragment 16 (Fig. 1c, Table 1 ) was designed de novo so as to explore this pocket, presumably involved also in the substraterecognition process. According to the modelling studies, we introduced a pyrazole moiety bearing a diol functionality to hydrogen bond to Lys101 (d(OH/ 2 HN-Lys101 ¼ 3.3Å), Asp430 (d(OH/O]C-Asp430 ¼ 2.8Å) and His434(d(OH/N-His434 ¼ 2.8Å). Although the pyrazolyl ring is not directly interacting with His51, it is believed to interfere with the catalytic role of His51, supposedly in the substrate-recognition process. 37 An ethylene linker (torsional angle s(N pyrazole -C-C-C imidazole ): À168 ) connects the pyrazolyl ring to an imidazolyl ring accommodated in the thiazolium pocket. In addition to the vander-Waals interactions with the side chains of Ile187 and Ile371, the imidazolyl ring is involved in a favourable S-aromatic interaction with the side-chain sulfur atom of Met349. The linker itself is also involved in numerous lipophilic contacts with the side chain of Ile187 and aromatic hydrogen atoms of Phe398. The synthesis of 16 relied on a regioselective alkylation of an appropriately protected imidazole followed by introduction of the pyrazole in an S N 2 reaction (Scheme S2 †). Biochemical evaluation of 16 resulted in an IC 50 of 762 AE 199 mM, with an experimentally derived LE of 0.32 kcal mol
À1
. Just like for fragment 15, the imidazolyl ring constitutes an equally versatile platform for further fragment growing and optimisation of 16. Based on the LEs, both 15 and 16 can be considered suitable starting points for further optimisation.
Determination of the binding mode in solution using the STI methodology
Before starting fragment optimisation, we validated the binding mode of the two fragment hits identied. To do so, we applied the novel STI NMR methodology (Fig. S3 †) for the rst designed fragments given the lack of a reliable crystallographic protocol and the opportunity to obtain information about the binding mode of small molecules in solution. In the rst stage, we conducted STD experiments with ligands 15 and 16 (Fig. S4 and S5 †). Both molecules showed STD enhancement in the presence of DXS, indicating that they bind to DXS. As expected, we observed no STD enhancement for the fragments in a buffer solution without DXS. The same observation holds true for trNOE peaks in a NOESY spectrum. For the third step of the methodology (INPHARMA), we chose deazathiamine (17) as a reference ligand for our studies (STD experiments shown in Fig. S6 †) . 34 17 is structurally related to TDP and docking studies supported our assumption that it binds in the TDP-binding pocket (Fig. S7 †) . Moreover, the experimental determination of the K i value for 17 (K i ¼ 151 AE 34 mM) conrmed that its mode of inhibition is competitive with respect to TDP, making it a suitable ligand for the INPHARMA methodology (Fig. S8 †) . ) calculated as DG ¼ ÀRT ln K 0 /K i , K i being the calculated inhibition constant, unless stated otherwise. N corresponds to the number of non-hydrogen atoms of that specic molecule.
c The K i value and mode of inhibition of 17 were determined experimentally. LE was derived from the experimental K i . Full details of the biochemical-assay conditions are provided in the ESI.
d 18 was isolated and tested as its ammonium tosylate salt.
In order to observe INPHARMA peaks in a spectrum, the ligands must have an off-rate from the target, which is large enough to ensure that several exchange events can take place during the NOESY mixing time of several 100 ms. When both molecules target the same binding pocket, magnetisation of the protons of the rst molecule will be transferred to the protein protons and back to the protons of the second molecule, when it is bound. 17 is a suitable choice in our case, given its IC 50 of 430 AE 68 mM against D. radiodurans DXS.
Whereas we recorded a NOESY spectrum of the ligand combination 17 and 15 ( Fig. S9 and S10 †) and were able to clearly observe INPHARMA peaks, we were unable to observe INPHARMA peaks for ligand combinations 17 with 16 and 15 with 16. We used the docking module FlexX to dock 15 and 16 into the crystal structure of D. radiodurans DXS. We generated 30 docking poses for each ligand and clustered them with an RMSD difference of 3Å using GROMACS to yield a set of representative and diverse binding modes. From every cluster, we used the structure with the best DG according to the scoring function HYDE in the LeadIT suite for the back-calculation of NMR data ( Fig. S11 and S12, Table S1 †). 38 We also docked 17 in the TDP-binding site of D. radiodurans DXS and, as expected, found the top-ranked poses to overlap with TDP, which we used as a reference for the INPHARMA calculations (Fig. S7 , Table S1 †). We back-calculated the NMR peak volumes of all three data sets (STD, trNOE and INPHARMA) for every docked pose, using the soware SpINPHARMA (http://www.inpharma.de) and scored the correlation between back-calculated and experimental data using the Pearson correlation coefficient to yield R STD , R trNOE and R INPHARMA . We then combined these to R STI by averaging and selected the structure pair with the highest score as the most accurate binding mode. The R STI values for every docked pose of each inhibitor are reported in Table S1 . † For 17, we identied three different and representative binding modes by docking (Fig. S7 †) , all of them preserving the p-p stacking interaction with Phe398 observed for TDP. Nevertheless, the hydroxyethylene tail seems to be rather exible and adopts different orientations in the three poses, being involved in hydrogen bonds with various amino acids (His82, His51 or His 304). We had observed before for another protein system that different binding modes of one ligand directly contribute to the spin diffusion and the NMR signals represent an average of them.
12 In order to better understand the binding behaviour of 17, we used all three representative binding poses as a starting point of an MD simulation for 1 ns (Fig. S13 †) . It is remarkable that only one pose maintains its binding mode during the MD simulation (Fig. S7, † docked pose 2) , conrming that this pose corresponds to the binding mode of 17 to D. radiodurans DXS in solution (Fig. 2b) . The best-scoring binding modes for 17 and 15 based on their R STI are shown in Fig. 2b . It is noteworthy that for ligand 15 the best scoring R STI (0.52) binding mode (Fig. S11 , † docked pose 1) is very similar to the modelled one (Fig. 1b) . In the other plausible binding mode proposed by the docking studies, 15 binds in the diphosphate pocket of TDP (Fig. S7 , † docked pose 2) but displays negative R STD and R INPHARMA values. The STI methodology was therefore able to clearly differentiate between both binding modes and allowed us to validate the modelled binding mode of 15. In the case of 16, we could only record STD and trNOE data. Docking identied two representative binding modes of 16 in the TDP-binding pocket of D. radiodurans DXS, which are shown in Fig. 3 (Fig. S12, Table S1 †). The absence of INPHARMA peaks could be explained by the small overlap between 16 and 17 in both poses. Owing to the lack of hydrogen-bonding interactions and the inherently ex-ible ethylene linker, the imidazolyl moiety presumably adopts various conformational states. MD simulations for 1 ns of the two selected representative poses further conrm this assumption. In fact, although the two poses are maintained during the simulation period, we observed several rotations of the imidazolyl moiety. The high degree of exibility combined with the small overlapping area with 17 are putatively the reasons why we only observed weak trNOE and no INPHARMA peaks. Regarding the R ST values, one of the two poses (Fig. S11 , † docked pose 2, R ST ¼ 0.45) seems to be slightly preferred over the other (Fig. S12 , † docked pose 1, R ST ¼ 0.42). Given that the validation of the binding mode within D. radiodurans DXS was possible just for 15 and given that 15 and 16 are equally amenable to follow-up synthesis, we focused our attention on the growing and optimisation of fragment 15.
Fragment growing and optimisation
To do so, we modelled and synthesised the compounds shown in Table 2 (Fig. S14 , Scheme S1-S6 †). The synthesis involves in every case a late-stage introduction of the moiety targeting the thiazolium and diphosphate pockets in an S N 2 reaction. Fragment 19 constitutes a regioisomer of 15 and we designed it so as to gain a hydrogen-bonding interaction with the side chain of Glu373, provided that the carboxylic acid is present in its protonated form. To circumvent the uncertainty related to the protonation state of the side chain of Glu373, we designed compound 20. According to the modelled pose, the amino group of 20 should form two strong hydrogen bonds with the side chain of Glu373 -whether protonated or not -as well as with the backbone C]O of Pro347. For both fragments, all the other interactions of the original fragment 15 are preserved. As shown in Table 2 , we observed only 20% and 0% inhibition at 2 mM for 19 and 20, respectively. Addressing the side chain of Glu373 seems therefore unreliable in terms of molecular recognition and addressing other amino-acid residues in the TDP-binding site of DXS would appear to be a better strategy for SBD.
To grow the fragment towards the diphosphate-binding pocket, we designed and tested 21 as a mixture of two regioisomers (21a and 21b), which displays an IC 50 value of 1.2 AE 0.2 mM. A possible explanation of the higher inhibitory potency of 21 with respect to 20 could be the capability of the aminoethylene linker to anchor 21 in a slightly different orientation with respect to 20, which might help the binding event to occur. This favourable anchoring both on the le-and right-hand sides of the molecule is probably responsible for the gain in potency. We accessed 22 conveniently in one step, starting from imidazole and the corresponding commercially available bromide. In the modelled pose, the p-stacking interaction with Phe398 is preserved as well as the two hydrogen bonds of 15. Moreover, the triuoromethyl group is involved in numerous lipophilic interactions with the side chains of Phe398, His124 and Ile371. It is also engaged in an electrostatic interaction with the positively charged guanidinium side chain of Arg401. The inhibitory potency of 22 (40% inhibition at 2 mM) can be considered comparable to that of 15 but its optimisation is more straightforward owing to the reduced number of synthetic steps. In addition, a benzene ring has more free substitution points compared to a pyridine ring. To increase the lipophilic contacts of 22, we expanded the imidazolyl ring into a benzimidazolyl moiety, leading to compound 23, which d Compound 21 has been tested as a mixture of 4-and 5-substituted regioisomers (21a + 21b).
e 40% inhibition at 2000 mM. interacts, according to our modelling, with Val80, His82 and Ile187. As a result, 23 (IC 50 ¼ 595 AE 81 mM) is three times more potent than the original fragment 15. The inhibitory potency of 23 is in the same range as that of the non-selective thiamine analogue deazathiamine (17; IC 50 ¼ 430 AE 68 mM), making 23 an attractive and novel thiamine analogue. The fact that this fragment was designed de novo could facilitate and enable subsequent tuning of the selectivity over human thiamine-or TDP-binding targets. We validated the binding mode of 23, using the STI method. Firstly, we recorded an STD spectrum of 23, which showed STD enhancement only in the presence of DXS, conrming the binding event (Fig. S15 †) . We observed the same in a trNOE spectrum (Fig. 4a) . In the subsequent NOESY spectrum of 23 and deazathiamine (17) we clearly observed INPHARMA peaks (Fig. 4a) , conrming that both compounds bind in the same pocket. As described above for 15, we generated three representative poses for 23 (Fig. S16 , Table S1 †). The docked pose of 23 displaying the best R STI score (R STI ¼ 0.57) is shown in Fig. 4b  (Fig. S16, † docked pose 3) . Two other plausible docking modes show binding of 23 in the diphosphate pocket (Fig. S16 , † docked pose 1, R STI ¼ 0.4) and the histidine-rich pocket (Fig. S16 , † docked pose 2, R STI ¼ 0.46), both having lower DG values than the pose shown in Fig. 4b , according to HYDE scoring (Table S1 †).
In the best pose according to the NMR studies (Fig. 4b) , the le-hand side of 23 maintains the same interactions with DXS with respect to the originally modelled pose, while the benzimidazolyl ring points into the histidine-rich pocket rather than towards the diphosphate pocket as is the case for the modelled pose of 23. We did not observe the modelled pose of 23 amongst the 30 docked poses but it was included in the evaluation and, not surprisingly, received a lower R STI score (R STI ¼ 0.29): this fact further validates the pose shown in Fig. 4b for 23 .
Taking advantage of the NMR studies, applied here for the rst time, we were able to investigate the binding mode of 23, setting the stage for further fragment-growing and optimisation to afford lead-like compounds with improved inhibitory potency, even in the case of a very complicate binding behaviour. It is worthwhile to underline that the binding pose validated with the STI approach taken here, differs from the pose obtained purely by modelling and that the structure-based fragment optimisation of 23 based on the modelled pose alone would have led to fragment growing in the wrong direction. This observation conrms that the validation of the binding mode of the fragments in the rst steps of the fragment-to-lead process is fundamental to render the whole process more efficient and less time-and material-consuming.
Conclusions
In conclusion, we have successfully applied the innovative NMR-based STI methodology for the rst time to a SBD project. In our de novo FBD of inhibitors of D. radiodurans DXS, the STI methodology was essential to validate the binding mode of the rst promising fragment (15, IC 50 ¼ 1.8 AE 0.5 mM) and enabled us to focus our efforts on just one fragment and perform further fragment-growing and optimisation leading to 23. Compound 23 is three times more potent than 15 (IC 50 ¼ 595 AE 81 mM) and about as potent as deazathiamine (17), making 23 an attractive thiamine analogue with the potential for better selectivity over other thiamine-or TDP-dependent enzymes, which will have to be realised in future cycles of optimisation. We investigated the binding mode of 23 using STI and found it to be different from the one modelled in the absence of experimental data. Our ndings show that the STI approach represents an attractive alternative to protein X-ray crystallography enabling SBD and FBD projects on targets for which a reliable crystallographic protocol is not available. A further advantage is that the binding mode in solution is derived. The STI methodology therefore holds the potential to nd application in a wide range of medicinal-chemistry or chemical-biology projects.
